INTRODUCTION
SMARD1 is a clinical variant of Spinal Muscular Atrophy (SMA), the second most frequent recessive autosomal disorder, and the most common genetic cause of death in childhood. SMA and SMARD1 are characterised by degeneration of lower motor neurons associated with progressive muscle paralysis. While the majority of SMA cases is due to mutations in the Survival Motor Neuron gene (SMN), (1) SMARD1 is caused by mutations in a different gene, the immunoglobulin µ-binding protein 2 gene (IGHMBP2) (2) (3) (4) (5) . SMARD1 patients suffer, in addition, from early impairment of the respiratory function due to the progressive affectation of the diaphragm (4) . Currently, there is no effective therapy for SMARD1 or SMA (6) , although there are some recent pilot clinical trials with positive results, see for example Mercuri, 2004 (7) .
The nmd mice suffer from a spontaneous autosomal recessive mutation in the mouse homologue gene (Ighmbp2), a member of a DNA/RNA helicase/ATPase protein family (8) (9) (10) . The defect consists in a single mutation (A to G) in intron 4, which produces a frame-shift and a premature stop of transcription (9) . The nmd mice display a similar phenotype to SMARD1 in infants. After the second week of life a progressive muscular weakness became apparent, progressing to a severe neurogenic atrophy of limbs muscles (8) (9) (10) (11) .
Neurotrophic factors have been considered as potential therapeutics for motor neurons diseases. This expectation has been based on the survivalpromoting properties of these molecules in animal embryonic motor neurons in culture, and their positive biological effects on nerves after axotomy and models of neurodegenerative diseases (12) (13) (14) (15) . Given the promising results obtained in most of the in vitro and in vivo assays in animal, exogenous neurotrophins has been used in clinical trials for patients suffering from Alzheimer disease, amyotrophic lateral sclerosis (ALS), peripheral neuropathies, Parkinson's and Hungtinton's disease.
Therapeutic trkC agonist antibodies are a promising approach for neurodegenerative diseases treatment in substitution of exogenous administration of neurotrophin-3 (NT-3) due to their high specificity to trkC. By contrast, NT-3 activates trkC and trkB, also trkA to a lesser extent, which are likely to produce more side effects. In addition, the long systemic half-life of antibodies can simplify treatment protocols.
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In the present study we perform an in vivo electrophysiological characterization of hind limb and diaphragm muscles of the nmd mouse model of SMARD1 and we address the possible beneficial effect of a monoclonal antibody (2256), agonist for trk C receptor, in this mouse model. The results show that in 2256-treated animals the loss of muscular strength was retarded and we found evidence of electrophysiological improvement of muscular function, consisting of restoration to normality of the level of depression during repetitive electrical stimulation. However, the decline in amplitude of the compound muscular action potential (CMAP) that occurs during the course of the disease, indicative of fibres loss, was not prevented, and not positive effect on survival was observed. 
RESULTS

Agonistic and pharmacokinetic properties of the trkC antibody 2256
Monoclonal antibodies against the human trkC extracellular domain were generated and screened for agonist activity using a cell based receptor tyrosine phosphorylation assay (16) . One monoclonal antibody, 2256, of the murine IgG 1 isotype was found to be a specific binder of trkC receptor without cross reactivity with trkA or trkB (J. Pons, data not shown). In the stable trkC expressing CHO cells, 2256 can induce trkC tyrosine phosphorylation trkC with the half maximum effective concentration (EC 50 ) of 0.87nM, whereas NT3 can do so with EC 50 of 1.09 nM (Fig 1A) . In terms of bioactivity, 2256 supported the survival of the embryonic rat trigeminal neuron cultures in a dose dependent fashion with an EC 50 of 2.58 nM, while NT3 has an EC 50 of 0.73pM (Fig. 1B) .
Next we investigated the pharmacokinetic property of 2256. We found the elimination phase half life (t 1/2 β) of 2256 to be ~199 hours when given intraperitoneally in mice. The value is consistent with the long circulating half life of an antibody, and it compares favourably with the published plasma half life of the endogenous trkC agonist, NT3, at around 1.28 minutes (17) .
Effect of 2256 on motor performance and survival in nmd mice
Mutant mice were indistinguishable from wild-type at birth, however mutants older than two weeks fed poorly and were easily identifiable from wild-type and heterozygous littermates by their lower body weigh ( Fig. 2A) . In addition, mutant mice develop a neuromuscular phenotype with a progressive loss of muscle mass and a marked decrease in fore and hind limbs grip strength (8-11). They could not stand erect, were unable to grasp a cage cover and showed progressive decreasing mass of girdle and hind muscles. We examined whether treatment with 2256 (5 mg/kg body weight, 2 times per week, starting at postnatal day 20, i.e. P20) could prevent the progressive loss of muscular function that occurs in nmd mice. The presence of the monoclonal antibody in serum was confirmed by ELISA analysis in mice injected with 2256 (n=10) or 6 differences in body weight between treated and untreated mice were found ( Fig.   2A,B) ; for example, at P60 body weight of 2256-treated mutants was 14.5 ± 0.2 g, n= 16, and 14.2 ± 0.83 g, n= 8, in untreated nmd mice.
Standard neurological examinations were performed in untreated and 2256-treated mice from 4-10 weeks of age. Treatment started after weaning (week 3). Untreated nmd mice (PBS-injected: 5 mice; not-injected: 9 mice) showed absolute lack of gripping strength in their fore limbs (Fig. 2C, filled squares), as assessed by the time the mice were able to be hanged with their fore limbs on a horizontal wire situated 10 cm above the floor (test time duration: 10 sec). However, in 2256-treated nmd mice the motor function impairment was delayed several weeks (Fig. 2C, triangles) . The mean time that PBS-injected nmd mice were able to maintain themselves on the wire was 0.8 ± 0.6 sec at four weeks of age (n=5), while at the same age in 2256-treated nmd mice it was 5.1 ± 1.6 sec (9 mice, 6 litters) (p<0.03), and 4.9 ±1.4 sec a week later (p<0.034). Heterozygous performance (Fig. 2C , grey squares; n=8) was not different from wild-type siblings (Fig. 2C, white squares ).
Mice were also tested for motor coordination (Fig. 2D ) by measuring the time they could be sustained in a rotating rod (test time duration: 10 sec).
Untreated nmd mice showed very poor balance in comparison with wild-type and heterozygous littermates (Fig. 2D,E) , (p<0.001) while in 2256-treated nmd mice, motor coordination was better one week after treatment (Fig. 2D,F) , (p<0.018). These results suggest that treatment with 2256 ameliorated disease progression in nmd mice.
To test whether 2256 affected survival, life spans of untreated and 2256-treated nmd mice were monitored from weaning to adulthood. No significant increase in life span was observed in 2256-treated mutant mice (Mann-Whitney Rank-Sum test), which median life duration was 69 days (n=15) in comparison with untreated nmd mice that had a median lifetime of 62 days (n=30). (Fig.   2G ).
Analyses of the electrical neuromuscular activity in nmd mice
In vivo EMG measurements were performed at P70 in the medial gastrocnemius (GN). We first stimulated the sciatic nerve by a single current pulse of supramaximal amplitude and recorded the electrical muscular response 7 (CMAP). The mean amplitude of the CMAP in the nmd mouse was decreased by more than half of the control value ( Fig. 3A; 22.9 ± 5.6 mV, n=10 and 48.8 ± 4.8 mV, n=14, respectively; p<0.002). The administration of 2256 had no significant effect on the mean amplitude of the CMAP in nmd (24 ± 3.1 mV, n=7) or wild-type mice at P70 (61 ± 9.2 mV, n=9) (Fig. 3A) , suggesting that the treatment protocol with 2256 was not able to stop the loss of motor fibres. In addition, as a positive control, we also treated a group of mutant mice with NT-4/5 (5 mg/kg body weight, 2 times per week, starting at P20). In this case the mean amplitude of the CMAP was not either recovered at P70 (26.7 ± 7.1 mV, n=3).
and NT-4/5 restore normal levels of high frequency-induced neuromuscular depression
To further investigate the neuromuscular electrical properties in nmd mice and the effect of 2256 and NT-4/5, we used paired-pulses, and short-train stimuli at different frequencies, and studied the electromyographic responses. In the GN, the amplitudes of the CMAP responses (A1 & A2) to paired-pulse supramaximal stimuli (10 ms interval) in wild-type and nmd mice were very different. In wildtype mice, the amplitude of the second CMAP (A2) was slightly larger, or equal to, than the first response (A1) (Fig. 3B) . In mutant mice, the amplitude of the second response was 21.4 ± 0.03% smaller than that of the first response (n=7) ( Figure 3F . These results suggest that both 2256 and NT-4/5 were able to restore, almost completely, the normal levels of high frequency-induced neuromuscular depression
Functional state of spindle afferent fibres in nmd mice
To asses the functional state of spindle afferent fibres in untreated and 2256-treated nmd mice, we recorded the EMG H-waves from the dorsal foot muscles, from where they are easily detectable. H-waves are produced by the activation of motor fibres by the sensory afferent circuit (inset Fig. 4A ) and are preceded by M-waves, which are elicited by the direct stimulation of nerve motor fibres (Fig. 4A) . The M/H-wave ratios were not different in wild-type (6.1 ± 1.3, n=6), untreated (6.1± 0.9, n=5) and 2256-treated nmd mice (7.6 ± 2.6, n=4), suggesting that muscle spindle fibres responsible for the stretch reflex in these at Pennsylvania State University on http://hmg.oxfordjournals.org/ Downloaded from muscles are not lost in mutants and that the treatment do not impaired this circuit.
In dorsal foot muscles, we have also studied the amount of depression of the EMG responses at different stimulation frequencies in nmd and control mice. There were not significant differences in mean quasi-steady-state depression of the CMAPs between wild type and nmd mice at frequencies from 10 to 50 Hz (Fig. 4B) . Only, at 100 Hz (Fig. 4C ) the amount of depression was slightly larger in nmd mice (40 ± 1.6%, n=6) than in wild-type (32 ± 2.85%, n=6) (P<0.036), suggesting that the foot dorsal muscles are less affected than the GN in this animal model.
MUNE analysis
The reduction in the amplitude of the CMAPs recorded in the GN of nmd mice suggests a decrease in the number of functional motor units. We have used motor unit number estimation (MUNE) to asses the degree of motor neuron loss in the GN of nmd mice. The number of functional motor units was determined at a late period in life of the mutant mice (P215-P230), and compared with that of control littermates. At this age, muscular atrophy of the hind limbs was very severe in the mutants while no signs of muscle wasting or strength decrement were observed in the heterozygous, which were phenotypically normal.
Successive incremental stimuli produced regular increments in motor unit potentials in the control (Fig. 5A ) while elicited abnormally large motor units potentials in nmd mice (Fig. 5B) . The final size of the potential after ten "successful" stimuli of increasing strength (i.e. stimuli that elicited an increment in the amplitude of the response) was much larger in the mutants than in the control sib mice due to the presence of large step increments in the mutants (giant motor units). Quantification of the size of the potentials are shown in the graphs in Figure 5C -F from two control (heterozygous) and two mutant littermates. The averaged single motor unit action potential (SMUAP) amplitude was 1.21 ± 0.62 mV (n=3) in nmd mice and 0.178 ± 0.06 mV (n=3) in control mice. Consequently, the MUNE was more than half reduced in nmd mice giving a mean value of 37.5 ± 11.4 (n=3), as compared with the heterozygous littermates that had 105.5 ± 12.4 (n=3) (P<0.0015). In addition, low intensity stimuli adequate for control mouse failed to elicit responses in the mutants, 
Diaphragmatic function in nmd mice
Respiratory failure is a characteristic of SMARD1 in humans, appearing already during the first year of life (4) . In order to assess whether there is also a defect at this level in nmd mice, and if so, what is the potential effect on it of the monoclonal antibody, the electrophysiological evaluation of the diaphragm was done under anaesthesia in twelve mice, older than ten weeks, divided in three groups: controls (wild-types and heterozygous, n=6), untreated nmd mice (n=3) and 2256-treated nmd mice (n=3). The electrical activity in the diaphragm is characterized by alternating bursts of spontaneous action potentials (inspiratory burst) and silent periods that coincide with expiration. Representative recordings from the diaphragm electrical activity in a control and in an untreated-nmd mouse are shown in the lower traces in Figure 6A ,B. In general, no postinspiratory electrical activity was observed in control and nmd mice.
Along the recordings, there was little variability in the duration of the inspiratory burst (T I ) and in the electrical activity during the burst. The respiratory frequency in control mice (140.2 ± 15.7 bpm, n=6) was similar to untreated-nmd (141.7 ± 6.2 bpm, n=3) and 2256-treated nmd mice (132.9 ± 22.6, n=3). However, there was a significant reduction (28%) in the mean duration of the inspiration (TI) in untreated-nmd mice (131.6 ± 4.1 ms) in comparison with control littermates (184.1 ± 11.7 ms) (P<0.005), suggesting that nmd mice, at late stages of life, have a mild abnormal inspiratory motor discharge. In 2256-treated nmd mice TI was 146.3 ± 8.2 ms, slightly larger than in untreated nmd mice but with not statistical significance at this small sample size (P<0.08) (Fig. 6C) . Histological examination of phrenic nerves' transverse sections (Fig. 6D ) in very old mutants (38 weeks) showed no significant differences in the number of myelinated axons between nmd (337±18 axons, n=2) and control littermates (364 ± 11
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DISCUSSION
We have studied the electromyographic characteristics of the nmd mice and tested the efficacy of an agonistic monoclonal antibody for trkC receptors (2256) on the clinical and electrophysiological signs of the disease.
Neuromuscular impairment in nmd mice
We observed some striking differences in nmd neuromuscular function. The major defects were a severe loss of motor nerve fibres and the inability of nmd mice to maintain a normal neuromuscular transmission with repetitive nerve stimulation. Normally, with repetitive nerve stimulation the CMAPs gradually decline in amplitude until reaching maximal depression after several pulses, with the maximal degree of depression directly proportional to the stimulation frequency. We have compared this physiological response in the GN of nmd and wild-type and found that nmd mice presented a much more severe depression in CMAP amplitudes than the littermate controls. It would be of interest to check if this behaviour is due to a defect at the presynaptic terminal, a reduction of postsynaptic efficacy or a shift of the muscular fibres to a more fatigable phenotype.
CMAP mean amplitude was reduced by more than 50% in nmd mice GN, at P70. This is in agreement with the reduction to 41% of lumbar motor neurons at 5 weeks described previously in this mutant (11) . At later stages of the disease (P150-230), the number of motor units remaining in the GN muscle was reduced to a 35% of the control value, which is not far from the previous estimation of 28% motor neurons remaining in the lumbar spinal cord at 12-14 weeks (11). The giant motor unit potentials had a high threshold of activation so they may recruit poorly. The severe loss of motor units, together with the inability to maintain effective transmission with repetitive stimuli, explains the diminished muscular strength of these animals animal model of motor neuron disease (14, 18, 19) . Based of these results, recombinant neurotrophic factors have been considered for more than a decade as potential therapeutic drugs for motor neuron diseases. However, the clinical trials done so far had encountered problems like inappropriate dosage, side effects, etc (20, 21) . Agonist monoclonal antibodies for neurotrophin receptors may, however, have some advantages over exogenous administrated neurotrophic factors, among them their specificity for a determinate receptor that may avoid side toxic effects, and their long systemic half-life that can simplify the treatment protocol. However, there are many aspect of the action of these molecules that need to be studied first in animal models. For example, in some models the rescue of motor neurons by neurotrophic factors was found to be transient in nature (22, 23) . In our experiments in nmd mice, 2256 retarded but not arrested disease progression.
It has been shown that ciliary neurotrophic factor (CNTF) and neurotrophin-3 (NT-3) can increase life-span in the mouse mutant pmn (progressive motor neuronopathy) (14, 24, 25) . Average life span of nmd mice has been described to be 54 days (10) . In our animal facility, untreated nmd mice median survival was similar (64 days). Treatment of nmd mice with 2256 from the 3 rd to the 11 th postnatal week did not increase significantly survival probability (median: 69 days). A possible explanation of the transitory effects of 2256 is that the relative high levels in plasma of the drug reached by some animals might have produced down regulation of trk C receptors, as has been shown in other studies with neurotrophins (26, 27) . If this is the case, therapeutic doses should be finely adjusted to avoid this effect.
Alternatively, 2256 was both less potent (~3000-fold difference in the EC 50 ) and less effective (~3 fold difference in the maximal effect) than NT3 in the neuronal survival bioassay. Thus a higher affinity/ activity version of the 2256 antibody might be required to achieve a longer and greater efficacy in the nmd mouse model.
Furthermore, lower motoneurons express both trkB and trkC receptors.
Activation of these and perhaps other receptors may be necessary for optimal therapeutic effect in the nmd mice. Indeed, we found that both 2256 and NT- 
Diaphragm electrical activity
In SMARD1, paralysis of the diaphragm appears during the first 13 month of life (2) 
MATERIALS AND METHODS
Mice breeding and genotype
B6.BLKS-nmd 2J mice were obtained from The Jackson Laboratory. Mice heterozygous for the nmd 2J were intercrossed and wild-type, heterozygous and mutant mice were used for the experiments. Mice were bred and maintained in standard conditions, except that for mutants food and water were available at the floor cage level.
Mice were genotyped as described (9) . Briefly, the point mutation, cause of the phenotype of the nmd mouse (homozygous for this mutation), generates a new DdeI restriction site that is absent in wild-type mice. The PCR assay to identify carriers in unaffected offspring was performed with two oligonucleotide primers that amplify an 694 bp PCR product, where the mutation is, being the forward primer: 5´-GCTGGAAACGATCACATACCG-3´ and the reverse primer:
5´-AGCTCCTGATGATCCAATGG-3´.
Mice treatment
Random groups of coded littermates mice of both sexes were injected 
Receptor tyrosine phosphorylation assay
The agonist activity of 2256 was evaluated in a cell-based trkC receptor tyrosine phosphorylation assay as previously described (16) . The half maximum effective concentrations were estimated by non-linear curve fitting using the Prism Software (GraphPad, San Diego).
Embryonic trigeminal neuron survival assay
Dissociated cultures of the trigeminal neurons were established from E12 Sprague Dawley rats. Dissected ganglia were trypsinized and dissociated by trituration (34) . The neurons were plated at a low density in 96 well tissue Finally the signals were detected by colorimetric reaction of HRP with TMB substrate (KPL, Denmark).
Neurological tests
Mutant and littermate control mice were subjected to standard neurological examination to quantify the onset and extension of the neuromuscular defect (SHIRPA protocol; http://www.mgu.har.mrc.ac.uk/mutabase/shirpa_summary.html) (35) .
For balance measurements mice were lowered onto a square thin stick by tail at Pennsylvania State University on http://hmg.oxfordjournals.org/ Downloaded from suspension, and allowed to stand on top. The stick was then rotated each second by hand for 10 seconds, and the ability of the mice to remain on the stick was measured in seconds.
For fore limb grip strength, mice were held above a horizontal wire and lowered to allow the fore limbs to grip the wire The ability of the mice to remain attached by the fore limbs was scored during 10 seconds.
Electromyography (EMG)
Intramuscular compound action potentials (CMAP) were recorded as previously described (36) Motor unit number estimation (MUNE) from the GN was calculated by dividing the averaged size of a single motor unit potential into a maximal CMAP that represents the sum of all motor units. Sampling of single motor unit potentials were done by the incremental method (37, 38) that consists in the application of finely controlled current in very small steps from sub threshold levels until the progressive recruitment of ten responses. Each current amplitude was applied three times and was considered stable, and therefore accepted, if they were identical. Individual motor unit amplitudes were obtained by subtracting amplitudes to each response to that of the previous response.
The average of the individual values gave us an estimation of the single motor unit action potential (SMUAP) size.
In vivo diaphragmatic recordings were performed by inserting a needle electrode behind the xyphoid process slightly off middle line to either site. The reference electrode was place on the chest and the ground electrode at the base of the tail. The diaphragm was readily identified by rhythmical burst discharges synchronous with respiration. The inspiratory discharges were quantified by the peak amplitude and area of the integral of the recording.
Inspiratory durations (T I ) were also analysed. Averaged values were calculated from six consecutives breathing cycles.
Studies were performed with coded mice so that the electromyographer was blinded as to which mice were being tested.
All data are reported as mean ± SEM. Statistical significance was evaluated using a Student's t-test. The criterion level for determination of statistical significance was set at P<0.05 for all experiments.
Histological analyses
Mice were sacrificed with an overdose of Ketamine/Xylazine and right side phrenic nerves were obtained close to their entry into the diaphragm muscle. 
